TABLE 2

Inhibition of ROS formation and toxification: translation to the clinics

TargetDrug ClassCompound NamePathologyClinical Trial IdentifierCurrent Status
NOX1/4NOX inhibitorsGKT137831Idiopathic pulmonary fibrosisNCT03865927Phase II
Type 2 diabetes and albuminuriaNCT02010242Completed (phase III in preparation)
Primary biliary cholangitis receiving ursodeoxycholic acidNCT03226067Phase II
NOSNOS inhibitorL-NMMAGLP-2–mediated intestinal lipoprotein releaseNCT03534661Phase I
Non–small-cell lung cancer, malignant melanoma, head and neck squamous cell carcinoma (three more)NCT03236935Phase I
Metastatic triple negative breast cancer patientsNCT02834403Phase II
2-IminobiotinPerinatal asphyxiaNCT01626924Phase II, recently terminated
Out-of-hospital cardiac arrestNCT02836340Phase II
VAS203Traumatic brain injuryNCT02794168Phase III
XOXO inhibitorAllopurinol (approved)Chronic gout
Ischemic stroke and transient ischemic attackNCT02122718Phase IV
Hypoxic-ischemic brain injury on neurocognitive outcomeNCT03162653Phase III
Complications of renal transplantNCT01332799Phase IV
Congestive heart failureNCT00181155Phase II
Chronic heart failureNCT00997542Phase IV
Febuxostat (approved)Gout
Endothelial function, cardiovascular system, hypertensionNCT03395977N/A
Hematologic malignancies of pediatric patients and adultsNCT03605212Phase II
Chronic renal diseaseNCT03425708Phase IV
TopiroxostatDiabetic nephropathyNCT02327754Phase II
HyperuricemiaNCT02837198Phase II
MAOMAO inhibitorSafinamide, selegilineParkinson disease
Rasagiline (approved)Macula-off retinal detachmentNCT02068625Phase IV
Toloxatone (approved)Depression
Pirlindole (approved)Depression, anxiety
Phenelzine, isocarboxazid, tranylcypromine (approved)Major depressive disorder
Moclobemide (approved)Addiction and major depression
MPOMPO inhibitorAZD3241Parkinson diseaseNCT01527695, NCT01603069Phase II
Multiple system atrophyNCT02388295Phase II (negative)
AZD4831Heart failureNCT03756285, NCT03611153Phase II
  • GLP-2, glucagon-like peptide-2; L-NMMA, L-NG-monomethyl arginine.